Literature DB >> 1435229

Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients.

A Zimran1, A Kay, T Gelbart, P Garver, D Thurston, A Saven, E Beutler.   

Abstract

We have reviewed our experiences with the clinical, laboratory, radiologic, and genetic features of 53 patients with Gaucher disease. Most were evaluated during early adult life, with a mean age of 33 years. Our patients were evaluated in a referral center, and therefore the data need to be interpreted with caution when applied to the general patient population, which includes a greater proportion of very mild cases. Thirty-nine patients were Ashkenazi Jews, 13 were non-Jewish and 1 was half-Jewish. The most common presenting symptom was bleeding related to splenomegaly and thrombocytopenia. The chronic symptoms, evaluated an average of 20 years after the diagnosis had been established, were mainly skeletal. Splenectomy had been performed in 43% of our patients and there was no evidence that this procedure accelerated the progression of liver and bone involvement. DNA from the patients was examined for 20 different mutations. The association between the 1226G/1226G genotype and a milder clinical course, and between the 1226G/84GG and 1226/1448C genotypes with more severe clinical manifestations, was confirmed. Repeated follow-up examinations in 29 patients revealed that in the majority of the patients, progression of the disease occurs during childhood, adolescence, or early adulthood with a marked tendency for stabilization thereafter. This observation suggests that Gaucher disease in most of the patients is not a relentless progressive disorder but a rather stable disorder during adulthood. The indications for the newly introduced intravenous enzyme replacement therapy as well as of future experimental treatments should be examined in the light of the natural history of the disease.

Entities:  

Mesh:

Year:  1992        PMID: 1435229

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


  64 in total

1.  Quality of life assessment in adults with type 1 Gaucher disease.

Authors:  B J Masek; K B Sims; C M Bove; M S Korson; P Short; D K Norman
Journal:  Qual Life Res       Date:  1999-05       Impact factor: 4.147

2.  Haemostatic abnormalities and lupus anticoagulant activity in patients with Gaucher disease type I.

Authors:  R Barone; G Giuffrida; R Musso; G Carpinteri; A Fiumara
Journal:  J Inherit Metab Dis       Date:  2000-06       Impact factor: 4.982

3.  Effects of switching from a reduced dose imiglucerase to velaglucerase in type 1 Gaucher disease: clinical and biochemical outcomes.

Authors:  Laura van Dussen; Timothy M Cox; Erik J Hendriks; Elizabeth Morris; Erik M Akkerman; Mario Maas; Johanna E M Groener; Johannes M F G Aerts; Patrick B Deegan; Carla E M Hollak
Journal:  Haematologica       Date:  2012-07-06       Impact factor: 9.941

4.  The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients.

Authors:  Tamar H Taddei; Katherine A Kacena; Mei Yang; Ruhua Yang; Advitya Malhotra; Michael Boxer; Kirk A Aleck; Gadi Rennert; Gregory M Pastores; Pramod K Mistry
Journal:  Am J Hematol       Date:  2009-04       Impact factor: 10.047

Review 5.  Current issues in enzyme therapy for Gaucher disease.

Authors:  G A Grabowski
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

6.  The risk of Parkinson's disease in type 1 Gaucher disease.

Authors:  Gilberto Bultron; Katherine Kacena; Daniel Pearson; Michael Boxer; Ruhua Yang; Swati Sathe; Gregory Pastores; Pramod K Mistry
Journal:  J Inherit Metab Dis       Date:  2010-02-23       Impact factor: 4.982

7.  Quality of life of brazilian patients with Gaucher disease and fabry disease.

Authors:  Fabiane Lopes Oliveira; Taciane Alegra; Alicia Dornelles; Bárbara Corrêa Krug; Cristina B O Netto; Neusa Sica da Rocha; Paulo D Picon; Ida Vanessa D Schwartz
Journal:  JIMD Rep       Date:  2012-04-18

8.  Pulmonary Gaucher's disease: high-resolution computed tomographic features.

Authors:  A Tunaci; Y M Berkmen; E Gökmen
Journal:  Pediatr Radiol       Date:  1995

9.  Life expectancy in Gaucher disease type 1.

Authors:  Neal J Weinreb; Patrick Deegan; Katherine A Kacena; Pramod Mistry; Gregory M Pastores; Priscilla Velentgas; Stephan vom Dahl
Journal:  Am J Hematol       Date:  2008-12       Impact factor: 10.047

10.  Bone events and evolution of biologic markers in Gaucher disease before and during treatment.

Authors:  Jérôme Stirnemann; Nadia Belmatoug; Corine Vincent; Olivier Fain; Bruno Fantin; France Mentré
Journal:  Arthritis Res Ther       Date:  2010-08-09       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.